Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms THYSU
- 13 Mar 2017 Results published in the European Journal of Cancer
- 10 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Jul 2009 Planned number of patients changed from 75 to 66 as reported by ClinicalTrials.gov.